A prospective observational registry evaluating clinical outcomes of Radium‐223 treatment in a nonstudy population

The ALSYMPCA study established a 3.6 month Overall Survival (OS) benefit in metastatic Castration Resistant Prostate Cancer (mCRPC) patients treated with Radium‐223 dichloride (Ra‐223) over placebo. Here we report clinical outcomes of Ra‐223 treatment in a nonstudy population. In this prospective re...

Descripción completa

Detalles Bibliográficos
Autores principales: Badrising, Sushil K., Louhanepessy, Rebecca D., van der Noort, Vincent, Coenen, Jules L.L.M., Hamberg, Paul, Beeker, Aart, Wagenaar, Nils, Lam, Marnix G.E.H., Celik, Filiz, Loosveld, Olaf J.L., Oostdijk, Ad, Zuetenhorst, Hanneke, Haanen, John B., Vegt, Erik, Zwart, Wilbert, Bergman, Andries M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383569/
https://www.ncbi.nlm.nih.gov/pubmed/31875956
http://dx.doi.org/10.1002/ijc.32851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383569/
https://www.ncbi.nlm.nih.gov/pubmed/31875956
http://dx.doi.org/10.1002/ijc.32851

Ejemplares similares